Evidence map›Paper›PMID 41820807›Full record

ReviewProtein science : a publication of the Protein Society2026

Toxic mechanisms of amyloid oligomers and therapeutic strategies.

Magdalena I Ivanova, Carmelo La Rosa, Ayyalusamy Ramamoorthy

Abstract readReview
In one paragraph

Review in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Toxic mechanisms of amyloid oligomers and therapeutic strategies.Protein science : a publication of the Protein Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Magdalena I IvanovaBiophysics Program, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-7290-3327
Carmelo La RosaDipartimento di Scienze Chimiche, Università degli Studi di Catania, Catania, Italy.
Ayyalusamy RamamoorthyBiophysics Program, University of Michigan, Ann Arbor, Michigan, USA.

Funding

Structural Investigation of Amylin Oligomers Associated to Type-2 DiabetesR01DK132214 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAMAMOORTHY, AYYALUSAMY · 2022 to 2025
$1.4M
NIH HHS DMR-2128556NIH HHS National Science Foundation Agreement & the StateNIH HHS R01DK132214
6 · The paper itself

Abstract

Amyloid oligomers are increasingly recognized as the major toxic contributors across protein-misfolding disorders. In this review, we cover mechanistic evidence showing how these transient and structurally heterogeneous oligomers disrupt cellular homeostasis by: (i) permeabilizing lipid membranes and forming ion-conducting pores; (ii) triggering endoplasmic reticulum (ER) stress and unfolded protein response (UPR), thereby compromising proteostasis via dysfunction of the ubiquitin-proteasome system (UPS) and autophagy; (iii) impairing mitochondrial function and disrupting redox balance; (iv) interfering with endosomal-lysosomal as well as axonal and synaptic trafficking; and (v) activating stress-kinase signaling and apoptotic pathways. In relation to therapeutic intervention, we review secretase-targeting strategies, conformation-selective antibodies, and their mixed clinical outcomes. An in-depth understanding of the toxic action of pathogenic oligomeric species will be critical for translating these mechanistic insights into effective therapies that comprehensively target oligomer toxicity.

Indexed as

AmyloidAnimalsEndoplasmic Reticulum StressHumansProteotoxic StressUnfolded Protein ResponseAmyloidamyloid diseaseneurodegenerationoligomersprionsprotein misfoldingtherapiestoxicity mechanisms

Identifiers

PMID41820807
PMCPMC13140465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.